Currently, ICB, especially anti-PD1 and anti-PDL1 antibodies, represent about 2/3 of cancer therapy trials, being applicable and obtaining optimistic results alone or in combination with conventional therapies for at least 50 types of cancer, in addition to having awarded its developers the Nobel Prize in 2018 [108]. The gene discussed is PDCD1; the disease is cancer.